Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Cubist Pharmaceuticals Inc. (NASDAQ: CBST) shares increased 4.57 percent to close at $73.21 a share Monday. The stock traded between $70.73 and $74.44 on volume 2.35 million shares traded. The company announced that total revenues are expected to be $1.1 billion for 2013, an increase of 14.0 percent year-over-year. Shares of Cubist Pharmaceuticals have gained approximately 60.0 percent in the past year.
Get more information on Cubist Pharmaceuticals free access to the in-depth equity report at:
www.FiveStarEquities.com/CBST
Dendreon Corporation (NASDAQ: DNDN) shares spiked 9.03 percent to close at $3.26 a share Monday. The stock traded between $3.08 and $3.48 on volume 17.18 million shares traded. The company announced that it expects net product revenue for the fourth quarter of 2013 to increase by 10.1 percent sequentially. Shares of Dendreon have fallen approximately 45.0 percent in the past year.
Get more information on Dendreon and free access to the in-depth equity report at:
www.FiveStarEquities.com/DNDN
Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) shares soared 40.35 percent to close at $1.60 a share Monday. The stock traded between $1.41 and $1.85 on volume 79.2 million shares traded. Roth Capital Markets has recently initiated coverage on the company with a “buy” rating and a price target of $3.00. Shares of Rexahn Pharmaceuticals have gained approximately 210.0 percent so far in 2014.
Get more information on Rexahn Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/RNN
Rosetta Genomics Ltd. (NASDAQ: ROSG) shares surged 18.18 percent to close at $3.77 a share Monday. The stock traded between $3.69 and $4.37 on volume of 7.25 million shares traded. The company announced that it has signed a master service provider agreement with an undisclosed major global biopharmaceutical company. Shares of Rosetta Genomics have fallen approximately 24.0 percent in the past year.
Get more information on Rosetta Genomics and free access to the in-depth equity report at:
www.FiveStarEquities.com/ROSG
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]